X4 Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on a special meeting of stockholders held by X4 Pharmaceuticals, Inc. on April 17, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol XFOR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Voting Results
Stockholders approved a proposal to amend the Restated Certificate of Incorporation to effect a reverse stock split. The approved ratio is between one-for-fifteen and one-for-thirty, with the exact ratio to be determined by the Board of Directors.
- Shares Outstanding (Record Date): 173,662,376
- Shares Present/Voted: 137,240,628 (approximately 79%)
- Proposal 1 Votes: 113,027,737 For; 23,988,610 Against; 224,281 Abstain
- Proposal 2: Not presented due to the approval of Proposal 1.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosure that capitalized terms are defined in the Definitive Proxy Statement filed on March 24, 2025.
Key Facts for Investor Verification
- Verify the exact reverse stock split ratio once announced by the Board of Directors.
- Confirm the effective date of the reverse stock split and the treatment of fractional shares.
- Review the Definitive Proxy Statement (Schedule 14A) filed on March 24, 2025, for details on the rationale for the split and the status of Proposal 2.